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Abstract
The neuronal ceroid lipofuscinoses (NCLs; Batten disease) are inherited neurodegenerative lysosomal storage
diseases with common clinical features of blindness and seizures culminating in premature death. Gene-therapy
strategies for these diseases depend on whether the missing activity is a secreted lysosomal protein taken up by
neighboring cells, or an intramembrane protein that requires careful targeting. Therapies are best developed in
animal models with large complex human-like brains. Lentiviral-mediated gene delivery to neural cell cultures
from normal sheep and sheep affected with an NCL resulted in green fluorescent protein (GFP) expression in
neurons and neuroblasts, more efficiently than in astrocytes. Similar transgene expression was obtained from
two constitutive promoters, the viral MND promoter and the human EF1a promoter. In vivo studies showed
stable and persistent GFP expression throughout the cell bodies, axons, and dendrites from intracortical injec-
tions and indicated ependymal and subependymal transduction. The sheep showed no ill effects from the
injections. These data support continuing gene-therapy trials in the sheep models of Batten disease.
Introduction
The neuronal ceroid lipofuscinoses (NCLs; Battendisease) are a group of inherited neurological diseases,
each of which is caused by mutations in a single gene. So far,
eight loci have been implicated in the various forms
(CLN1,2,3,5,6,7,8,10), each with a number of disease-causing
mutations (see www.ucl.ac.uk/ncl). These are lysosomal
storage diseases with onset at various ages. Clinical symp-
toms include blindness, seizures, and loss of motor function,
and ultimately lead to premature death. As a group, theNCLs
represent the most common childhood neurodegenerative
disease with an estimated incidence of 1:12,500 live births
(Rider and Rider, 1988).
Studies in human NCLs are very restricted, and progress
to understand the biochemistry, pathogenesis, and thera-
peutic options depends largely on studying genetically de-
fined animal models. Viral vector-mediated gene-therapy
trials have been used to deliver palmitoyl protein thioester-
ase I (PPT1) and tripeptidyl peptidase I (TPP1), the enzymes
deficient in infantile (CLN1) and late-infantile (CLN2) NCL,
to knockout mouse models, and a clinical trial is ongoing in
human patients with CLN2 mutations. Neonatal delivery of
PPT1 partially reversed some pathological and behavioral
characteristics of infantile NCL in mice, but did not change
the age of death (Griffey et al., 2004, 2005, 2006). Delivering
TPP1 to TPP1-deficient mice was more effective if given early
in the disease progression (Sondhi et al., 2007, 2008). Viral-
mediated gene transfer has also been a relative success in
other lysosomal storage disorders caused by defects in sol-
uble lysosomal proteins, most notably in both mouse and
large-animal models of mucopolysaccharidoses (Haskins,
2009).
Scaling up from a small lissencephalic rodent brain to a
large one replete with gyri and sulci presents a number of
problems, and large-animal studies are particularly impor-
tant for translating advances in viral-mediated gene ther-
apy to the clinic. Issues to be resolved include ensuring that
transduction is stable and that transduction and expression
do not adversely affect the brain. As it is not practicable to
transduce most cells in the brain, priority needs to be given
to identify target cells that are accessible. The larger brain
requires the development of much more sophisticated in-
jection and surgical techniques than are necessary in mice.
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Two naturally occurring forms of CLN5 and CLN6 NCL
have been found in sheep, and well established flocks are
available for model studies ( Jolly et al., 2002; Tammen et al.,
2006; Frugier et al., 2008). Both are classical subunit c of
mitochondrial ATP synthase–storing forms of NCL (Chen
et al., 2004; Frugier et al., 2008). The sheep brain has a similar
complex structure and is more comparable in size to the
human brain; also, sheep have a similar physiology and
genetic organization. Neuropathology in these NCLs in both
humans and sheep is dominated by cortical atrophy and
neurodegeneration, and symptoms in the sheep closely
parallel those in the human diseases. Although there is pa-
thology in the human brainstem and thalamus at end-stage
disease, no significant changes in these regions are seen in
the sheep. This is possibly due to the sheep not being as
intensively supported at end-stage disease, so that the degree
of progression may not be as advanced as human disease.
Even with this caveat, the similarities make the sheep par-
ticularly good experimental models of the human diseases.
Mutations in CLN5 result in the loss of function of an
uncharacterized soluble mannose-6-phosphate–tagged lyso-
somal protein (Holmberg et al., 2004; Sleat et al., 2005, 2006).
Along with CLN1, CLN2, and CLN10, which also encode
soluble lysosomal proteins, this gene is an attractive gene-
therapy candidate because of the phenomenon of cross-
correction, where soluble lysosomal proteins can be secreted
from cells and taken up by other cells via endocytosis. In
contrast, the other form in sheep, CLN6, arises from muta-
tions in a nonsecreted, endoplasmic reticulum membrane–
associated protein (Gao et al., 2002; Wheeler et al., 2002;
Heine et al., 2004; Mole et al., 2004). The products of CLN3,
CLN7, and CLN8 are also membrane-associated intracellular
proteins. These are likely to require careful targeting of a
vector that spreads widely in the brain and has a high effi-
ciency, unless the critical products of processing by these
proteins are themselves secreted and endocytosed, such as
neuroprotective factors that promote cell survival.
Lentiviruses are a family of complex retroviruses that,
together with adeno-associated viruses (AAVs), are com-
monly used to derive vectors for gene therapy. Both these
vectors have been tested previously in models of lysosomal
storage disorders in mice. Lentiviruses were successfully
used to treat a mouse model of mucopolysaccharidoses
(Brooks et al., 2002) and to test the spread of virus and se-
cretion of TPP1 in the mouse brain (Haskell et al., 2003).
As a prelude to gene-therapy trials in NCL sheep, we set
out to determine whether recombinant lentiviral vectors
would target sheep neural cells. Previously developed
methods to culture neural cells isolated from fetal sheep re-
sult in a mixed population including neural precursors
(neuroblasts), mature neurons, astrocytes, and microglia
(Kay et al., 2006). These cultures were used to test the
transduction and tropism (as measured by transgene ex-
pression) of lentiviral vectors for sheep neural cells. The ef-
ficiency of gene transfer between affected and normal
unaffected sheep and the expression of transgenes from two
different promoters, the myeloid proliferative U3 enhancer
element (MND) (Challita et al., 1995; Kobayashi et al., 2005)
and the human elongation factor 1a promoter (EF1a), were
tested. MND is a strong constitutively active viral promoter
previously tested in hematopoietic cells (Avile´s Mendoza
et al., 2001) and muscle (Richard et al., 2008). EF1a is also
constitutively active and is commonly used in viral vectors
for transgene expression in a variety of tissues, including the
brain ( Jakobsson et al., 2003). The lentiviral vectors were then
used to test gene transfer in vivo, by direct stereotactic in-
jection into the cerebrum or cerebrospinal fluid (CSF) of
adult control and CLN6-affected sheep. The results of this
study pave the way for future work aimed at targeting
subsets of neural cells in NCL and other neurodegenerative
disorders where sheep may be used as models of human
disease.
Materials and Methods
Viral constructs and packaging
Approval for the use of recombinant lentiviral vectors was
obtained from ERMA New Zealand (GMD03091). HIV-1–
derived lentiviral plasmids (Meyerrose et al., 2008) expres-
sing green fluorescent protein (GFP) under the myeloid
proliferative U3 enhancer element (pLVMNDGFP) or human
elongation factor 1a promoter (pLVEF1aGFP) (see Fig. 1a)
were packaged using a third generation packaging system
(Zufferey et al., 1998). In brief, 5106 293FT cells (Invitrogen,
Carlsbad, CA) in a T75 flask (Nunc A/S, Roskilde, Denmark)
were transfected with 11.25mg of pLV, 7.3 mg of pLP1, 2.8 mg
of pLP2, and 3.95 mg of pVSV-G (Zufferey et al., 1998) in
OptiMEM containing Lipofectamine-2000 (Invitrogen).
Medium containing virus was recovered 48 and 72hr post
transfection and concentrated by ultracentrifugation in a
Beckman SW28 rotor (Beckman Coulter, Brea, CA) at 112,500
gmax for 90min at 48C, resuspended in phosphate-buffered
saline (PBS) containing 40 g/L lactose, and stored at 808C.
Functional viral titers, determined by serial dilution on hu-
man HT1080 cells (ATCC, Manassas, VA), ranged from
1109 to 1.31010 transducing units (TU)/ml. RNA genome
titers were determined using a Quick Titer Lentivirus
Quantitation kit (Cell Biolabs Inc., San Diego, CA) and were
proportional to functional titers between constructs. For
in vivo work, 8 mg/ml Polybrene (Sigma–Aldrich, Castle Hill,
NSW, Australia) was added to the viral solution just prior to
injection.
Viral transduction of neural cell cultures
Frozen stocks of sheep fetal neural cells, isolated as pre-
viously described (Kay et al., 2006), were thawed rapidly,
counted, and plated at 1105 cells/cm2 on 10mg/ml poly-L-
lysine–coated 12-mm coverslips in 24-well plates (Nunc).
Medium was Dulbecco’s modified Eagle’s medium/F12 (1:1)
containing 2mM KCl, 2mM glutamine, penicillin/strepto-
mycin, and 2% B27 supplement (Invitrogen). Half-volume
medium changes were performed every 3 days. Cultures
grown for 8–12 days were transduced with 2105 viral
particles/well. This resulted in a multiplicity of infection of
0.6 based on HT1080 titer, prevented saturating the cells with
multiple viral particles per cell, and allowed determination
of relative tropism for each cell type. Five days later, trans-
duced cultures were either fixed with 4% paraformaldehyde
(PFA) for immunocytochemistry or lysed in 125mM Tris-
HCl, pH 6.8, 2.5% sodium dodecyl sulfate, and 2.5% glycerol
for western blotting. Protein concentrations were estimated
using a Bio-Rad DC protein assay kit (Bio-Rad, Auckland,
New Zealand) and bovine serum albumin as the standard.
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Western blotting
To quantify GFP expression from the MND and EF1a
promoters, lysates from transduced and control cells were
separated on NuPAGE 4–20% gels (Invitrogen) before
transfer to polyvinylidene fluoride membranes in a Bio-Rad
Mini Trans-Blot at 100 V for 1 hr. Membranes were blocked
with 5% nonfat milk powder in Tris-buffered saline, pH 7.6,
with 1% Tween-20 (TBS-T) for 1 hr before overnight incu-
bation with antibodies against GFP (rabbit anti-GFP; Abcam,
Cambridge, UK; ab290; 1:10,000) in 1% nonfat milk powder
in TBS-T. After washing, the membranes were incubated in
TBS-T containing 1% nonfat milk powder and goat anti-
rabbit horseradish peroxidase (1:10,000; GE Healthcare,
Amersham, UK), then detected using ECL-Plus reagents (GE
Healthcare) and visualized using a Fujifilm Las Imager 3000.
Membranes were then rinsed in TBS-T, reblocked, and pro-
bed with an anti-actin antibody (rabbit anti-actin 20–33;
Sigma–Aldrich, A5060; 1:5,000), used to normalize loadings.
Immunocytochemistry
Cells were washed briefly in PBS, before blocking in 3%
normal goat serum. Astrocytes were recognized by reaction
to mouse anti-glial fibrillary acidic protein (GFAP) (Sigma–
Aldrich, G3803; 1:500), neurons by reaction to mouse
anti-microtubule-associated protein 2 (MAP2) (Millipore,
Billerica, MA, MAB3518; 1:500), and neuroblasts by reaction
to mouse anti-polysialated neuronal cell adhesion molecule
(PSA-NCAM) (Millipore, MAB5324; 1:1,000). GFP expression
was detected with rabbit anti-GFP (Abcam, ab290; 1:20,000)
that was preincubated on normal nontransduced cells to
remove nonspecific binding. Secondary antibodies were goat
anti-mouse Alexa 568 (Invitrogen, A-11031) or goat anti-
rabbit 488 (Invitrogen, A-11008). Following immunolabeling,
cells were incubated in 4’,6-diamidino-2-phenylindole
(DAPI; Sigma–Aldrich; 100 ng/ml), for 5min at room tem-
perature, to detect nuclei and determine total cell number,
and then mounted on glass slides in ProLong Gold antifade
(Invitrogen) for imaging. For each well, 20 fields at
400magnification were imaged and the proportions of
GFP-positive cells and total cells of each type calculated.
Statistical analyses
Statistical analyses were performed using the R statistical
software (www.r-project.org). An analysis of variance model
was used to assess the effects of each experimental factor on
the proportion of GFP-positive cells, these being affected and
control cells, each cell type, and the two promoters, MND
and EF1a. Main effects were included for each factor, along
with second-order interaction terms for each factor pair.
Specific contrasts of interest (e.g., cell-type specific differ-
ences in transduction efficiency) were also estimated using
linear combinations of model coefficients. Coefficients and
contrasts with p values less than 0.05 were taken to be sta-
tistically significant. Numbers are reported as the mean
 SEM.
Animals and in vivo viral injections
Sheep. All animal work was approved by the Lincoln
University Animal Ethics Committee and complied with the
New Zealand Animal Welfare Act, 1999. Homozygous
affected South Hampshire lambs were generated by mating
heterozygous ewes to homozygous affected rams, and the
genotype was determined using a discriminatory c.822G>A
polymorphism in the CLN6 gene (Tammen et al., 2006). At
the time of vector injection, the sheep were 8 months of age
and in good health. Normal age-matched sheep were treated
as controls.
In vivo viral injections. Sheep were fasted overnight.
Anesthesia was induced with a mixture of ketamine (7.5mg/
kg live weight) and diazepam (0.3mg/kg live weight) given
intravenously. Then the sheep were intubated (9.5-mm
cuffed endotracheal tube) and maintained on a mixture
of halothane (2–4%) and oxygen, within a closed circuit
system.
Viral vector was injected intracortically into two affected
and two control sheep. With the sheep in the prone position,
the head was secured for injection in a stereotactic frame
(Kopf, model 1630; David Kopf Instruments, Tujunga, CA),
and the surgical site was clipped and prepared for surgery
by repeated scrubs with 4% chlorhexidine gluconate and
polyvinylpyrrolidone iodine followed by draping. Following
a medial skin incision and retraction of underlying muscu-
lature and fascia, two 3-mm holes were drilled through the
frontal bone 5mm either side of the midline and 47mm
rostral to the occipital ridge. To establish the depth to the
tissue-ventricle interface, a 20-gauge needle was attached to
a fine tube containing a column of sterile saline trypan blue
solution and lowered into the brain using a stereotaxic ma-
nipulator. The ventricular interface was indicated by the
positive flow of CSF once the ventricle was reached. The
needle was then withdrawn 5mm, and a 10-ml Hamilton
syringe with a 26-gauge needle was threaded down the 20
gauge to be 4mm proud of the end and 1mm superficial to
the tissue-ventricle interface. One microliter of viral vector
solution containing 1.3108 TU in 10 ml was infused over
1min. The complete needle unit was then withdrawn si-
multaneously 1mm over a minute before the next 1 ml of
virus was discharged, until all 10ml of the viral solution was
infused. The procedure was repeated on the other side of the
brain. The wound was closed with a continuous subcuticular
suture followed by interrupted skin sutures that were re-
moved subsequently. An analgesic (buprenorphine HCl) was
administered intramuscularly (330mg/animal), as was a
mixture of procaine and benzathine penicillin (12,000 IU/kg),
and the animals were observed until full recovery.
An additional affected and control animal pair were in-
jected with 1109 TU in 100ml directly into the CSF at the
cisterna magnum.
Treated animals were housed indoors, fed a mixed ration
of lucerne chaff and balanced sheep nuts, and monitored
daily for any adverse reactions.
Immunohistochemistry
Brains were perfusion-fixed at postmortem via the carotid
artery with 10% formalin in 0.9% NaCl after they were flu-
shed with warm 0.9% NaCl. They were left in fixative for
7 days, then equilibrated over 7 days in cryoprotectant,
20% sucrose and 10% ethylene glycol in 0.9% NaCl, and
stored frozen at 808C until sectioned. Serial sagittal sections
(50mm) were cut on a freezing sliding microtome (Microm,
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Walldorf, Germany) and then stored at 208C in cryopro-
tective solution in 96-well plates.
All antibodies were diluted in 10% normal goat serum in
PBS containing 0.3% Triton X-100. To identify the gene in-
jection site and spread of the virus, every 12th section was
stained for GFP. Sections were thawed and blocked in 15%
normal goat serum for 60min, and incubated overnight at
48C, in rabbit polyclonal anti-GFP (Abcam, ab290; 1:20,000)
that had been incubated with normal sheep brain sections
for 1 hr to remove nonspecific labeling. Immunoreactivity
was detected with fluorescent Alexa-488 goat anti-rabbit IgG
(Invitrogen, A-11008; 1:2,000) for 4 hr at room temperature.
In other cases, the secondary antibody was biotinylated goat
anti-rabbit IgG (Sigma–Aldrich, B7389; 1:1,000) for 4 hr at
room temperature, followed by ExtrAvidin peroxidase
(Sigma–Aldrich, E2886) for 4hr at room temperature, which
was detected with a solution of 0.5mg/ml 3,3’-diaminobenzidine
(DAB; Sigma–Aldrich, D5637) and 0.01% H2O2 in PBS.
Parallel series of sections, identified following initial
screening of sections around the approximate injection site,
were double-labeled with GFP and either GFAP or the
fluorescent Nissl dye, NeuroTrace (Invitrogen, N21482), as
markers of transduced glial cells and neurons, respectively.
A standard cresyl violet Nissl stain (Oswald et al., 2005) was
applied to some sections from around the injection site,
which were examined for any signs of injection-related pa-
thology. For GFAP and GFP immunofluorescence, sections
were blocked in 15% normal goat serum for 60min, then
incubated in rabbit anti-cow GFAP (DAKO, Denmark,
Z0334; 1:1,000) overnight at 48C. The secondary antibody,
Alexa-594 goat anti-rabbit IgG (Invitrogen, A-11012; 1:1,000),
was applied for 4 hr at room temperature. Sections were then
fixed in 4% PFA for 20min. GFP was detected using rabbit
anti-GFP Alexa-488 conjugated antibody (Invitrogen, A-
21311; 1:500), overnight at 48C.
Parallel series of sections were stained for GFP with rabbit
polyclonal anti-GFP, 1:2,000 (as above), and NeuroTrace,
1:150 in PBS, for 60min at room temperature.
Sections were mounted in a solution of 0.5% gelatin and
0.05% chromium potassium sulfate on glass slides, air-dried,
and coverslipped using glycerol. Negative control sections,
in which either the primary or secondary antibody was
omitted, were included in all staining runs. No im-
munostaining was observed in any of the negative control
sections.
Results
Lentiviral vectors transduce sheep neural cells in vitro
Before embarking on in vivo studies, transduction, cell
tropism, and transgene expression from two lentiviral con-
structs were tested in both control and affected sheep fetal
neuronal cultures. These mixed cultures contained the target
cells of interest; neurons, neuroblasts, and astrocytes. Eight
to twelve days after plating, neural cultures were transduced
with lentiviral vectors encoding GFP under the control of
either MND, a viral promoter (Fig. 1a and b), or EF1a, a
constitutive human promoter (Fig. 1a and f) and double-
labeled for GFP and either MAP2 to identify neurons (Fig. 1c
and g), PSA-NCAM to identify neuroblasts (Fig. 1d and h),
or GFAP to identify astrocytes (Fig. 1e and i). Transgene
expression was observed in all three cell types in cultures
from both promoters, and there was no significant difference
in the proportion of cells of each type expressing GFP be-
tween promoters ( p¼ 0.69). That there was little difference in
overall GFP expression from either promoter was confirmed
by western blotting of cells from two independent control
preparations transduced with an equivalent number of viral
particles (Fig. 1j).
As in normal cultures, transduction of affected cultures
resulted in transgene expression in neurons (Fig. 2a), neu-
roblasts (Fig. 2b), and astrocytes (Fig. 2c). On average, 20%
neurons, 24% neuroblasts, and 18% astrocytes were identi-
fied in cultures (Table 1), and there was no significant dif-
ference ( p> 0.05) between the proportions of these cell types
in the affected and normal cultures.
If the virus transduced all cell types equally (without
tropism for one cell type over another), the percentage of
transduced GFP-positive cells of each cell type should be
similar to the percentage of that cell type in culture (Table 1).
However, the percentages of transduced cells identified as
neurons or neuroblasts in both affected and normal cultures
were significantly greater ( p¼ 5.910–12 and 9.710–11, re-
spectively) than expected compared with their abundance in
the cultures. In addition, there was a suggestion that the
affected cultures were more efficiently transduced than
controls ( p¼ 0.029), driven largely by a difference observed
in the transduction of affected astrocytes (Table 1).
Lentiviral-mediated gene transfer to adult sheep brain
As there were no significant differences between the per-
formance and expression from the two promoters being
tested, the MND vector was chosen as representative for
in vivo studies. Lentiviral particles were injected bilaterally
into the brain of two affected and two normal 8-month-old
animals, rostral to the occipital ridge, aiming for just dorsal
to the ventricle (Fig. 3a). Transduction of cells via injection
directly into the CSF at the cisterna magnum was also ex-
plored in an affected and a control animal.
None of the sheep showed ill effects from the injections.
Recovery from the anesthesia was uneventful, and all the
animals resumed normal eating within 24 hr. Rectal tem-
peratures remained normal throughout the 3 weeks they
were monitored after the operations. Growth rates and
general condition remained the same as those of the unin-
jected controls.
Brains were taken from a control and an affected animal
40 days after the intracerebral injections and from the other
pair after 80 days. Immunohistochemistry revealed GFP ex-
pression in cells along the extent of the needle track through
the line of the injection (Fig. 3b and c) from all four animals.
The intense fluorescence and high density of expressing cells
at the injection site suggested potent lentivirus transduction,
which declined further away from the center of injection.
GFP-positive cells were detected in the brain parenchyma up
to 2.5mm rostral-caudal and lateral to the injection site. Both
neurons (Fig. 3d and e) and astrocytes (Fig. 3f and g) were
similarly transduced in affected and normal sheep brain.
A heterogeneous population of neurons was transduced,
with numerous multipolar and bipolar neurons displaying
GFP immunoreactivity. Multipolar neurons with polygonal
cell soma were colabeled with NeuroTrace (Fig. 3d). Neurons
with spheroid cell soma and bipolar projections exhibited
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GFP expression throughout the axon hillock and up to
150 mm along axonal and dendritic extensions (Fig. 3e). GFP
expression was also evident within stellate cell bodies,
characteristic of mature astrocytes. These were confirmed to
be astrocytes by colabeling with GFAP (Fig. 3f and g). Both
transduced neurons and astrocytes were evident along the
extent of the injection track.
Control and affected animals showed no discernible dif-
ference in the number of transduced cells, staining intensity,
or cell types transduced. Transduction and expression were
stable with no differences in GFP expression being noted
between the animals analyzed 40 and 80 days post injection.
Examination of Nissl-stained sections confirmed that there
were no signs of inflammation or other pathology around the
injection sites detectable in Nissl-stained sections (data not
shown), and the GFP-expressing cells retained healthy
morphologies typical of their type.
Transduced cells were also revealed along the entire rostral-
caudal extent of the ependyma lining the lateral ventricle
in the subventricular region. This was particularly evident
in one affected animal that also displayed a smaller and less
intensely stained region of transduced cells corresponding to
the injection site within the brain parenchyma (Fig. 3h). The
injection protocol was designed to inject the vector into the
subventricular zone (SVZ); it was anticipated that the hole
from the needle would close sufficiently to block leakage into
the ventricle, but it is not clear how much of the injection
volume was retained in the cerebrum. In the case of this
animal, the widespread gene transfer along the rostral, cau-
dal, and lateral extent of the ependyma of the lateral ventricle
and lesser staining within the brain parenchyma indicate that
there may have been considerable leakage into the ventricle.
GFP was strongly expressed within the cell soma of cuboidal
ependymal cells arranged in a single layer lining the lateral
ventricle (Fig. 3h and i). In one affected animal, transgene
expression was also observed in subependymal cell bodies in
the region 30 mm from the ventricular surface. This region
contained transduced cells with large cell soma and multiple
GFP-expressing processes extending vertically above the
soma or radiating laterally, and which extended at least
another 50 mm into the SVZ region (Fig. 3j). These cells may
be typical of type B astrocytes, believed to represent the
FIG. 1. Lentiviral-mediated gene transfer to sheep neural cells in vitro. (a) Lentiviral-derived transgene constructs used to
deliver GFP to neural cells in culture and into the sheep brain. LTR, long terminal repeat; RRE, rev response element; cPPT,
central polypurine tract; MND, myeloid sarcoma virus promoter; EF1a, human elongation factor 1a promoter; GFP, green
fluorescent protein; WPRE, woodchuck hepatitis virus posttranscriptional regulatory element. (b–i) Neural cells from normal
embryonic day 60 sheep transduced with MND (b–e) or EF1a (f–i) GFP viruses and analyzed 5 days post transduction. Both
promoters mediated expression in neurons, confirmed by labeling of GFP-positive cells with MAP2 (c, g), in PSA-NCAM–
positive neuroblasts (d, h), and in GFAP-positive astrocytes (e, i). Scale bars¼ 100 mm (b and f) and 20mm (c–e, g–i). (j)
Western blot of nontransduced () and transduced HT1080 cells and neural cells from two sheep transduced with MND or
EF1a (EF) promoter lentiviral vectors probed with GFP and actin antibodies. The relative expression of GFP was similar with
both promoters.
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neural stem cells of the SVZ. Additionally, occasional cells
with a characteristic, unipolar morphology consistent with
migrating neuroblasts were seen in this affected animal
deeper within the subependymal region, at a distance of up
to 200mm from the ventricular surface (Fig. 3j, arrow). They
were not evident along the entire extent of the SVZ, the few
revealed by immunohistochemistry being present at more
rostral regions.
A thorough examination of sagittal sections across the
mediolateral extent of each brain hemisphere revealed no
transduced cells 40 days post injection in the two animals in
which the vector was injected directly into the CSF at the
cisterna magnum.
Discussion
Here, we report the first demonstration of lentiviral-
mediated gene transfer to sheep neural cells and transgenic
protein production in vivo. Transductions in the sheep brain
were stable, with GFP-expressing cells equally evident 40
and 80 days post injection. The cell types transduced in vivo
correlated with the in vitro studies. Neither the vector nor the
expression of GFP caused observable pathology to trans-
duced or neighboring cells. Although expression from the
intracortical injections was most intense along the line of the
injection site, some cells were specifically labeled up to
2.5mm from this site, indicating either migration of trans-
duced cells or spread of the viral particles from the sites of
injection. Furthermore, transgene expression was noted at
considerable distances along the axons/dendrites, an im-
portant factor for secretion of soluble transgene products to
distal regions of the brain. Because of the leakage into the
ventricle, noted by labeling of the ventricular surface, it is not
possible to know what the optimal distribution from in-
tracortical injections might be, and future experiments are
required to address this.
The transduction of cells along the extent of the ventricular
surface (Fig. 3h–j) probably results from this leakage. It has
been suggested that subsets of ependymal cells function as
multipotent neural stem cells in adult mice ( Johansson et al.,
1999); however, most studies suggest that type B astrocytes
FIG. 2. Lentiviral-mediated gene transfer to affected neural cells in vitro transduced with lentivirus-GFP (green) and labeled
to detect (a) MAP2-positive neurons (red; arrow points to transduced neuron), (b) PSA-NCAM–positive neuroblasts, and (c)
GFAP-positive astrocytes. Scale bar¼ 100mm (a–c).
Table 1. Lentiviral Tropism for Sheep Neurons
and Neuroblasts















Neurons 21.3 1.4 29.7 2.3 18.4 2.3 30.2 4.4
Neuroblasts 25.4 4.1 36.0 4.4 22.3 5.4 32.8 6.6
Astrocytes 19.3 3.2 3.7 0.8 15.9 3.1 9.4 4.4
Embryonic day 60 neural cells were cultured from three normal
and three affected sheep and transduced with lentivirus expressing
GFP. The proportion of each cell type in cultures was determined as
a percentage of total DAPI-positive cells. The proportion of GFP-
positive cells of each cell type was also calculated. The proportions of
neurons and neuroblasts transduced were significantly higher than
expected in comparison with their presence in cultures. Data
presented are means SEM.
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in the SVZ are the bona fide adult neural stem cells (Chiasson
et al., 1999; Doetsch et al., 1999a; Laywell et al., 2000). Al-
though type B astrocytic cells have their cell bodies located at
the apical edge of the SVZ, a subpopulation may send oc-
casional processes through the ependymal layer to contact
the ventricle (Doetsch et al., 1999b; Conover et al., 2000), and
thus provide physical access to neural stem cells for vectors
present in the lateral ventricle. The identity of these stem
cells has been the subject of intense research, and it is now
well accepted that some of the GFAP-expressing cells are
FIG. 3. Lentiviral-mediated gene transfer to the sheep brain. (a) Sheep brain and the viral injection site anterior to the
occipital ridge. (b, c) Low-power images of GFP-positive transduced cells in the cortex of affected sheep (b) 40 days or (c) 80
days post surgery. Scale bars¼ 200 mm. (d–g) Transduced GFP-positive cells in affected and control sheep brains. GFP-
positive cells colabeled (arrows) with NeuroTrace to label neuronal cell soma red (d, affected; e, control) and astrocytes (f,
affected; g, control). Scale bar¼ 40 mm (d–g). (h–j) Leakage of the virus into the ventricle resulted in widespread transduction
of ependymal cells along the ventricular surface in affected sheep shown 80 days post surgery. Transduced cells with large
multiprocessed morphology and occasional smaller unipolar cells (arrow) were found in the SVZ (i, j). Scale bars¼ 200 mm (h)
and 100 mm (i, j).
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stem cells in rodent and human SVZs. Confirmation of stem
cell transduction would provide an additional route for
spread of the gene product via migration of stem cell prog-
eny into the degenerating brain. The few cells identified with
neuroblast morphology in vivo (Fig. 3j) and the tropism for
neuroblasts in vitro suggest that lentiviruses may be targeted
to neural progenitor cells in the sheep brain. The dogma in
LSD therapeutics is that 5% of normal enzyme activity is
sufficient to restore normal cellular function. Expression
from lentiviral vectors can provide supraconcentrations of
secreted protein (e.g., Brooks et al., 2002; Haskell et al., 2003),
which spreads from the transduced cell into the parenchyma.
Therefore, transduction of a large number of neuroblasts and
migration to the degenerating cerebral cortex may provide a
wider distribution of the soluble lysosomal protein than
possible without multiple injections directly into affected
regions of the brain. It remains to be seen whether this is a
viable therapeutic target. Further advances and testing of
other vector pseudotypes and injection protocols targeting
multiple regions are required to improve gene transfer to this
potential therapeutic target. These results also indicate that
intraventricular injection may be a route to the transduction
of ependymal cells and secretion of soluble gene products
into the CSF and surrounding parenchyma cells.
Our study injected a relatively small volume and number
of particles in comparison with recent studies in monkey and
humans. In a human trial in CLN2-deficient patients, 1012
AAV particles were injected into 12 sites across the rostral-
caudal extent of the cerebral cortex (Worgall et al., 2008). This
compares with the 108 particles injected here into the sheep
brain, which is only an order of magnitude smaller. In a
recent monkey study, between 33 and 199ml of AAV was
injected into the brainstem or thalamus of four cynomologus
monkeys, which have a brain size similar to that of sheep
(Aguilar Salegio et al., 2010). Interestingly, this study showed
that vector spread was directly proportional to the injection
volume albeit that the larger injections also contained more
viral particles. Larger injections did not cause significant
adverse mechanical injury. These and other studies using
lentivirus (Kitagawa et al., 2007; Ahmed et al., 2010) suggest
that vector spread could be improved by increasing injection
volumes.
The lack of transduction of the ventricular cells or any
other following injection into the cisterna magnum, even
though the vector number and injection volume was 10 times
that of the cortical injections, demonstrates that this is not a
viable route to expose this vector to the ventricular surface or
other parts of a larger brain, despite positive indications in
rodent studies. CSF from the lateral ventricles travels to
the cisterna magnum and, from this large reservoir, bathes
the spinal cord and then the brain before being returned
to the circulation via the arachnoid villi. Based on the extent
of incidental labeling of ependymal and subependymal cells
lining the lateral ventricles resulting from our parenchymal
injections, it is likely that virus transduced ependyma adja-
cent to the cisterna magnum injection site, and there was
probably too little vector left to be effective by the time the
CSF had completed its return journey to the brain. This lack
of ventricular transduction by this route could be a feature of
the size of the CNS of the species used, as well as the par-
ticular vector. A study of intrathecal delivery of lentiviral
vectors into neonatal mice reported patchy transduction of
meninges and secretion of a soluble enzyme into the CSF
(Fedorova et al., 2006), and intrathecal delivery of AAV1
vectors into a mouse model of metachromatic leukodystropy
resulted in widespread transduction within the brain (Iwa-
moto et al., 2009). Injecting microgram quantities of a-L-
iduronidase weekly into the cisterna magnum of a canine
model of mucopolysaccharidosis-I achieved functional con-
centrations in the brain and associated membranes (Kakkis
et al., 2004). Evidently, size of the rodent CNS is not a hin-
drance to the transduction of cells via the intrathecal delivery
of vectors, whereas it is in sheep. This indicates that reports
of positive transgene expression via this route in rodent
models of disease do not ensure that human studies will be
successful. Testing therapies in large-animal models with
large and complicated CNS is a valuable prerequisite for
recognizing and overcoming potential hurdles.
Only one previous study has tested viral gene transfer in
sheep, targeting RNA interference to the hypothalamus us-
ing AAV vectors (Dufourny et al., 2008). In addition to utility
in the naturally occurring genetic models of NCL developed
in sheep (Tammen et al., 2006; Frugier et al., 2008), their
similar brain structure and size to humans makes them
useful as large-animal models in other diseases. For instance,
sheep models have also been developed for conditions
such as perinatal hypoxia–ischemia (Dean et al., 2008), Tay-
Sachs disease (Torres et al., 2010), and Huntington’s disease
( Jacobsen et al., 2010), which may be amenable to gene therapy.
Lentiviral vectors pseudotyped with vesicular stomatitis
virus glycoprotein (VSV-G) have been extensively charac-
terized in rodents (Brooks et al., 2002; Watson et al., 2002;
Jakobsson et al., 2003). Tropism in these cases and in the
current study is measured by transgene expression, assum-
ing that the promoters are ubiquitously expressed in all cell
types. However, as in other model organisms, VSV-G–
pseudotyped lentiviral vectors under ubiquitous promoters
favored transgene expression in neurons rather than glial
cells (Desmaris et al., 2001; Jakobsson et al., 2003). Our in vitro
studies confirm this transgene expression bias in sheep
neural cultures, establishing cell-culture–based analysis as a
valuable tool for determination of vector tropism, viral vec-
tor function, and promoter activity prior to time-consuming
in vivo studies. In rodent brain, pseudotyping with a lyssa-
viral envelope enhances axonal uptake and retrograde
transport to distal neurons (Desmaris et al., 2001), which
could be explored in sheep. The persistence of neural pro-
genitor cells in the SVZ of rodents and humans (Reynolds
and Weiss, 1992; Eriksson et al., 1998; Curtis et al., 2003)
suggests this zone as a target. The incidental transduction of
this region via leakage into the ventricles (Fig. 3h–j) suggests
intraventricular injection as a route.
Three naturally occurring sheep NCL mutations have been
identified in orthologues of the genes CLN5 and CLN6 re-
presenting NCLs associated with those affecting soluble
lysosomal proteins and those associated with membrane-
associated proteins, respectively, and well established flocks
are available (Tammen et al., 2006; Frugier et al., 2008). These
subgroups may require different treatment strategies, the
former being amenable to cross-correction from transduced
cells supplying the missing protein to surrounding paren-
chyma, whereas delivery of corrected gene products for
the membrane-associated NCLs will require a vector that
spreads widely in the brain at high efficiency. This may
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require transduction of targeted stem cells in vivo that can
replace compromised cells, unless the membrane-associated
protein processes some factor that is secreted and taken up
by other cells.
Although few clinical trials have been approved using
lentiviral vectors, gene-therapy trials have begun for one
form of Batten disease in humans, CLN2 deficiency (late-
infantile NCL) using AAV vectors (Worgall et al., 2008). The
well-developed sheep models provide an ideal resource to
study vector and gene product spread, optimal timing of
interventions, and injection-site targets to optimize func-
tional effects.
In summary, this study provides the first evidence of
lentiviral-mediated gene transfer to the sheep brain, and an
approach with which to test further gene-therapy strategies
and vectors in NCLs.
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